Market LIVE
Published markets; coverage varies by country
Product profile · United States

ANORO ELLIPTA

 ·  Patent Litigation & Settlement History ↓

IngredientUMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE
Application typeNDA
Application203975
Product001
Dosage formPOWDER
RouteINHALATION
StrengthEQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH
Approval date2013-12-18
Marketing statusPrescription
Status event—
ApplicantGLAXOSMITHKLINE
Product source

Current GenericRadar decision

Year2030
SelectionCANDIDATE
ReviewFINAL
Anchor typeDS_EQUIVALENT_PATENT
Anchor date2030-11-29
Patent anchor2030-11-29
Exclusivity anchor2018-12-18
Protection date2030-11-29
First Final ANDA—
Status event—

NO_POST_ANCHOR_TAIL; Canonical 2030-11-29; latest tail NO_POST_ANCHOR_TAIL

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
85113042027-06-14DP/U U-1476———
———
85113042027-12-14— ————
—2027-12-14—
85113042027-12-14ORANGE_BOOK U-1476NNSYSTEM
English description not available.
—2027-12-14—
74888272027-12-18DS/DP ————
———
74888272027-12-18ORANGE_BOOK —YNTRUE_DS
English description not available.
———
110902942030-11-29U U-3203———
———
110902942030-11-29ORANGE_BOOK U-3203NYDS_EQUIVALENT
English description not available.
———
123969862030-11-29DP ————
———
123969862030-11-29ORANGE_BOOK —NYDS_EQUIVALENT
English description not available.
———
97507262030-11-29DP ————
———
97507262030-11-29ORANGE_BOOK —NYDS_EQUIVALENT
English description not available.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NP2013-12-182016-12-18English description not available.NN—Source
NCE2013-05-102018-05-10NEW CHEMICAL ENTITYYY2018-05-10Source
NCE2013-12-182018-12-18NEW CHEMICAL ENTITYYY2018-12-18Source
M-2452019-06-092022-06-09ADDITIONAL INFORMATION ADDED TO THE LABELING BASED ON SAFETY AND EFFICACY DATA FROM THE IMPACT TRIALNN—Source

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (10)
TypeDateRoleBasisSource
PATENT2027-12-14HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2027-12-18HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2030-11-29CANONICAL_ANCHOREnglish description not available.Source
PATENT2030-11-29CANONICAL_ANCHOREnglish description not available.Source
PATENT2030-11-29CANONICAL_ANCHOREnglish description not available.Source
REGULATORY_EXCLUSIVITY—HISTORICAL_CONTEXTADDITIONAL INFORMATION ADDED TO THE LABELING BASED ON SAFETY AND EFFICACY DATA FROM THE IMPACT TRIALSource
REGULATORY_EXCLUSIVITY—HISTORICAL_CONTEXTNEW CHEMICAL ENTITYSource
REGULATORY_EXCLUSIVITY—HISTORICAL_CONTEXTNEW CHEMICAL ENTITYSource
REGULATORY_EXCLUSIVITY—HISTORICAL_CONTEXTEnglish description not available.Source
REGULATORY_STATUS2030-11-29CANONICAL_DECISIONNO_POST_ANCHOR_TAIL; Canonical 2030-11-29; latest tail NO_POST_ANCHOR_TAILSource
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.